Bloomlife, a leader in maternal health technology, has successfully raised $12.2 million in a Series A funding round, marking a significant step forward in its mission to advance maternal healthcare. The funding round was led by Kapor Capital and European investor Noshaq and included follow-on investments from existing backers such as RH Capital, 15th Rock Ventures, The Grove Foundation, Stardust Equity, and Lean Square.
The investment follows Bloomlife’s recent FDA clearance for its MFM-Pro device, a wearable that monitors both maternal and fetal heart rates. The newly secured funds will support Bloomlife’s commercial expansion and the development and FDA clearance of a second proprietary device, further solidifying the company’s position in the rapidly growing maternal health technology sector.
Eric Dy, Ph.D., Co-Founder and CEO of Bloomlife, commented on the evolving landscape of maternal healthcare in an interview: “The healthcare industry is increasingly receptive to reevaluating how maternal care is delivered. The shifts we’ve seen, particularly following the COVID-19 pandemic, highlight the need for more efficient, accessible, and patient-centered care models.”
Reflecting on the current state of maternal care, Dy added, “Current practices in maternal healthcare are often outdated and cumbersome, relying heavily on frequent in-person appointments and manual processes. By digitizing these systems, we can greatly enhance the patient experience, making it easier for expectant mothers to monitor and manage their health. Our solution provides a centralized platform where all relevant data is easily accessible to patients and their care teams, leading to more informed decision-making and better health outcomes.”
Bloomlife’s platform aims to address inefficiencies and gaps in maternal care by providing a comprehensive remote care solution. The company has already expanded its offerings to include hypertension and diabetes management, with plans to incorporate maternal mental health screening and social determinants of health assessments. This holistic approach is in line with Dy’s vision of a “full stack” maternal care platform that integrates screening, risk identification, and management with clinical services integrated into their partner’s existing workflows.
“We’ve shown that these services provide benefits to both patients and providers, and can be delivered in a financially viable way,” Dy explained. The company has already secured reimbursement across 18 payers, including both commercial insurers and Medicaid, demonstrating the financial sustainability of their model.
Looking ahead, Dy anticipates significant consolidation in the maternal health tech space over the next two years. He sees Bloomlife playing a key role in this consolidation, leveraging partnerships and collaborations to create a comprehensive maternal health platform.
The urgency of addressing maternal health challenges is underscored by alarming statistics from the World Health Organization, which reports that a woman dies every two minutes due to pregnancy or childbirth complications. Bloomlife views technology as a critical tool in addressing this global crisis, with their FDA-cleared devices and comprehensive platform positioned to make a significant impact.
Dy also touched on the increasing focus on maternal health technology among various stakeholders: “The fact that the maternal health crisis is now front and center in public consciousness is also influencing professional societies, who recognize that traditional approaches are not working and that new solutions must be tried. This paves the way for solutions like ours.”
With the new funding, Bloomlife is well-positioned to continue its mission of improving maternal health outcomes through innovative technology. As the company expands its commercial reach and develops new products, it remains focused on its ultimate goal: shifting care to the home, improving access, enhancing adherence to clinical guidelines, and empowering both mothers and care teams with the tools and information they need to improve birth outcomes.
